Business
Endonovo Therapeutics Expands SofPulse® Sales to Plastic Surgery Centers
Endonovo Therapeutics Expands SofPulse® Sales to Plastic Surgery Centers.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\") today announced sales of SofPulse® units to multiple Plastic Surgery Centers. SofPulse® is Endonovo’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema. SofPulse® represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. This non-invasive and non-pharmacologic therapy has no known side effects and presents no potential for overdose or dependency as SofPulse® is not reliant on any narcotic to produce pain and edema reduction. SofPulse® has been effectively utilized and studied extensively in soft tissue postoperative pain management showing significant clinically proven results for the reduction of postoperative pain and edema. Learn more at www.sofpulse.com Endonovo Therapeutics CEO Alan Collier stated, “SofPulse® main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures. With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse® demonstrates different applications for its use.” As SofPulse® expands into the out-patient Ambulatory Surgical Center (ASC) market, Collier further states, “We are quickly becoming the go to pain and edema reduction option for many out-patient surgical procedures preformed at ASC’s throughout the US. These centers provide patients with cosmetic and reconstructive procedures resulting in a need for postoperative pain management. Many of the plastic surgery centers have state-of-the-art surgical suites and recovery rooms equipped to hospital standards and we continue working with these centers and completing evaluations. Although in the nascent stages of expanding into fully certified office-based surgery centers, we recognize the large and growing market size allowing us to be well poised to capitalize on this opportunity.” About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® the...